Reeve Emma 4

Accession 0001680329-25-000006

CIK 0001070081other

View on SEC.gov Company Profile

Filed

Oct 6, 8:00 PM ET

Accepted

Oct 7, 5:20 PM ET

Size

32.0 KB

Accession

0001680329-25-000006

Insider Transaction Report

Form 4

Period: 2025-10-03

PTC THERAPEUTICS, INC.PTCT

Reeve Emma

Director

Transactions

Exercise/Conversion
Common Stock
2025-10-03$39.42/sh+10,000$394,200→ 20,332 total
Sale
Common Stock
2025-10-03$66.10/sh−4,037$266,846→ 12,216 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-10-03−10,000→ 0 total
Exercise: $33.63Exp: 2033-01-04→ Common Stock (10,000 underlying)
Sale
Common Stock
2025-10-03$66.87/sh−2,381$159,217→ 10,332 total
Sale
Common Stock
2025-10-03$65.02/sh−2,163$140,638→ 15,081 total
Sale
Common Stock
2025-10-03$66.93/sh−1,600$107,088→ 10,332 total
Exercise/Conversion
Common Stock
2025-10-03$33.63/sh+8,650$290,900→ 18,982 total
Sale
Common Stock
2025-10-03$65.05/sh−2,729$177,521→ 16,253 total
Sale
Common Stock
2025-10-03$66.09/sh−4,591$303,419→ 12,713 total
Exercise/Conversion
Common Stock
2025-10-03$33.02/sh+6,912$228,234→ 17,244 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-10-03−6,912→ 0 total
Exercise: $33.02Exp: 2029-01-21→ Common Stock (6,912 underlying)
Sale
Common Stock
2025-10-03$65.09/sh−3,028$197,093→ 17,304 total
Sale
Common Stock
2025-10-03$66.11/sh−3,149$208,180→ 11,932 total
Sale
Common Stock
2025-10-03$66.89/sh−1,884$126,021→ 10,332 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-10-03−8,650→ 0 total
Exercise: $33.63Exp: 2028-12-13→ Common Stock (8,650 underlying)

Footnotes (11)

[F1]This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.
[F10]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.61 to $67.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
[F11]Currently exercisable.
[F2]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
[F3]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
[F4]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.50 to $67.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
[F5]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
[F6]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
[F7]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.61 to $67.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
[F8]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
[F9]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.46 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Documents

1 file

4
form4-10072025_051012.xmlPrimary

Issuer

PTC THERAPEUTICS, INC.

CIK 0001070081

→

Entity typeother

Related Parties

filerCIK 0001680329

Filing Metadata

Form type: 4
Filed: Oct 6, 8:00 PM ET
Accepted: Oct 7, 5:20 PM ET
Size: 32.0 KB

View on SEC.gov